As an outlook, next steps may include a longitudinal investigation to establish a correlation of described immune-related surrogate imaging markers with peripheral expansion of corresponding T-cell subpopulations on several time points within durvalumab maintenance treatment, especially in PD-L1 tumor cells positive and negative patient cohorts. This evidence concerns the gene CD274 and neoplasm.